A Bay­er part­ner slims down, trim­ming R&D and en­act­ing lay­offs, to bet­ter fo­cus on the pair's prostate can­cer work

A Bay­er part­ner that co-de­vel­oped an FDA-ap­proved prostate can­cer drug is join­ing some of its biotech com­pa­tri­ots and tak­ing out its re­struc­tur­ing kit, an­nounc­ing a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER